This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO | MicrobiomeTrials
← Back to trials NCT03841734
Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO Completed PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2020-02-04Est. Completion: 2023-07-26
Enrollment target: 8 participantsLocations CH de Cannes, Cannes, France Other microbiome trials you might be interested in Giant Cell Arteritis (GCA)
B cells are a component of the immune system which appear be important in causing all forms of cardiovascular disease. U…
Edinburgh, United Kingdom Est. completion Apr 2029
Takayasu's Arteritis Giant Cell Arteritis Polyarteritis Nodosa Relapsing Polychondritis ANCA-Associated Vasculitis
Background:
\- Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many me…
Bethesda, United States Est. completion Jan 1, 2050